736 related articles for article (PubMed ID: 14501602)
1. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
[TBL] [Abstract][Full Text] [Related]
3. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
4. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
5. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
[TBL] [Abstract][Full Text] [Related]
7. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
[TBL] [Abstract][Full Text] [Related]
8. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
9. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Siris ES; Baim S; Nattiv A
Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
[TBL] [Abstract][Full Text] [Related]
10. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment.
Miller PD; Siris ES; Barrett-Connor E; Faulkner KG; Wehren LE; Abbott TA; Chen YT; Berger ML; Santora AC; Sherwood LM
J Bone Miner Res; 2002 Dec; 17(12):2222-30. PubMed ID: 12469916
[TBL] [Abstract][Full Text] [Related]
11. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study.
Abrahamsen B; Vestergaard P; Rud B; Bärenholdt O; Jensen JE; Nielsen SP; Mosekilde L; Brixen K
J Bone Miner Res; 2006 May; 21(5):796-800. PubMed ID: 16734396
[TBL] [Abstract][Full Text] [Related]
12. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
Reginster JY
J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
[TBL] [Abstract][Full Text] [Related]
13. Fracture risk and bone density of peri- and early postmenopausal women with uterine leiomyomas.
Randell KM; Honkanen RJ; Tuppurainen MT; Kröger H; Jurvelin JS; Saarikoski S
Maturitas; 2006 Feb; 53(3):333-42. PubMed ID: 16019169
[TBL] [Abstract][Full Text] [Related]
14. A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study.
Abrahamsen B; Madsen JS; Tofteng CL; Stilgren L; Bladbjerg EM; Kristensen SR; Brixen K; Mosekilde L
J Bone Miner Res; 2003 Apr; 18(4):723-9. PubMed ID: 12674333
[TBL] [Abstract][Full Text] [Related]
15. Does hormone-replacement therapy prevent fractures in early postmenopausal women?
Randell KM; Honkanen RJ; Kröger H; Saarikoski S
J Bone Miner Res; 2002 Mar; 17(3):528-33. PubMed ID: 11874244
[TBL] [Abstract][Full Text] [Related]
16. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
[TBL] [Abstract][Full Text] [Related]
17. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment.
Yates J; Barrett-Connor E; Barlas S; Chen YT; Miller PD; Siris ES
Obstet Gynecol; 2004 Mar; 103(3):440-6. PubMed ID: 14990403
[TBL] [Abstract][Full Text] [Related]
18. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
Maddalozzo GF; Widrick JJ; Cardinal BJ; Winters-Stone KM; Hoffman MA; Snow CM
Bone; 2007 May; 40(5):1244-51. PubMed ID: 17291843
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study.
Jensen LB; Vestergaard P; Hermann AP; Gram J; Eiken P; Abrahamsen B; Brot C; Kolthoff N; Sørensen OH; Beck-Nielsen H; Nielsen SP; Charles P; Mosekilde L
J Bone Miner Res; 2003 Feb; 18(2):333-42. PubMed ID: 12568411
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
